Anaphylaxis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Anaphylaxis Treatment Market is segmented By Drug Class (Adrenergic Agonists, Antihistamines (Diphenhydramine (Benadryl), Hydroxyzine (Vistaril)), H2 Receptor Antagonists (Cimetidine (Tagamet), Ranitidine (Zantac), Famotidine (Pepcid)), Bronchodilators (Albuterol (Proventil HFA, Ventolin HFA, ProAir HFA)), Corticosteroids (Methylprednisolone (Solu-Medrol), Prednisone), Positive Inotropic Agents (Glucagon (GlucaGen)), Vasopressors (Dopamine (Intropin)), By Route of Administration (Parenteral, Oral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Anaphylaxis Treatment Market Size

Anaphylaxis Treatment Market size was valued at USD 5,453.60 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 6.60% over the forecast period 2024-2031.

Anaphylaxis is a severe allergic reaction to the venom, food, or medication. It is mostly caused by a bee sting or eating foods known to cause allergies, such as peanuts or tree nuts. Common causes of anaphylaxis include medication, peanuts, tree nuts, insect stings, fish, shellfish, and milk. Other causes may include exercise and latex. The primary drug treatments for acute anaphylactic reactions are epinephrine and H1 antihistamines. The global anaphylaxis treatment Market growth is driven by several factors, such growing prevalence of allergies and their awareness among customers and increasing advancement in the product with cost-effective solutions.

Anaphylaxis Treatment Market Summary

For more insights - Download the Sample

Anaphylaxis Treatment Market Dynamics

Growing cases of anaphylaxis and rising demand for self-administered drugs are driving the market growth.

The rise in the patient pool suffering from allergies globally is a major factor driving the anaphylaxis treatment market. The incidence of Anaphylaxis in the U.S. and the U.K. is increasing daily. According to Statista data, in 2021, around 14% of people in the United States will suffer from Anaphylaxis. According to the AAFA study published in the Journal of Allergy and Clinical Immunology (JACI), Anaphylaxis, a life-threatening allergic reaction, is common in the U.S. It occurs in about one in 50 Americans. Many believe the rate is higher than that. It is probably closer to one in 20. Clinical databases such as PubMed have captured the growing prevalence of Anaphylaxis. According to the World Allergy Organization, Where it was possible to provide estimates for the number of deaths each year due to Anaphylaxis, this ranged from 5 or less in Hungary, 44 in Japan, to 500 in both China and the United States of America. Prevalence rates of Anaphylaxis ranged from 2% of the population in the United States of America to 0.1% of the population in Korea and 0.6-1% of the population in Australia. Therefore, the growing incidence of Anaphylaxis is likely to increase the high uptake of the anaphylaxis treatment market.

Anaphylaxis Treatment Market Segmentation

Antihistamines segment is projected to be the dominant segment in the market during the forecast period.

Antihistamines are primarily effective against the cutaneous effects of anaphylaxis. Also may help antagonize cardiac and respiratory effects; should be used routinely in most cases of anaphylaxis. IV administration is preferable when a rapid effect is desired. IM dosing also is effective but has a slower onset than IV and may cause local tissue irritation. Antihistamines segment has two sub-segments given below,

Diphenhydramine (Benadryl): Diphenhydramine has a long history of efficacy and relative safety. It has an FDA indication for anaphylaxis. IV administration provides faster onset of action.

Hydroxyzine (Vistaril): Hydroxyzine is an H1 antihistamine. It may suppress histamine activity in the subcortical region of the CNS.

The H2 Receptor Antagonists segment held a significant market share in the forecast period. These agents block the effects of released histamine at H2 receptors, thereby treating vasodilation, possibly some cardiac effects, and glandular hypersecretion. H2 blockers with H1 blockers have the additive benefit over H1 blockers alone in treating anaphylaxis. Ranitidine (Zantac) is probably preferred over cimetidine (Tagamet) in anaphylaxis in light of the risk for hypotension with rapidly infused cimetidine and the multiple, complex drug interactions with cimetidine. Famotidine (Pepcid) IV is another good alternative. H2 Receptor Antagonists have three sub-segments as given below,

Cimetidine (Tagamet): Many H2 blockers are available. Cimetidine is the prototype drug; other agents have much less evidence of effectiveness in anaphylaxis.

Ranitidine (Zantac): Ranitidine is an H2 antagonist, which, when combined with an H1 type, may be useful in treating allergic reactions that do not respond to H1 antagonists alone.

Famotidine (Pepcid): H2 antagonist that when combined with an H1 type, may be useful in treating allergic reactions that do not respond to H1 antagonists alone.

COVID-19 Impact on Anaphylaxis Treatment Market Growth

Positive impact on the global anaphylaxis treatment market.

Lockdown regulations have been relaxed in most countries, but people are reluctant to visit doctors in person due to the fear of spreading coronavirus (COVID-19). Thus, companies in the anaphylaxis treatment market are adopting telemedicine as individuals prefer remote healthcare services during the COVID-19 era. The demand for telehealth technology will rise dramatically during the forecast period. Telemedicine apps are helping to expedite the process of quality medical care in the sphere of warts therapeutics. Also, growing awareness of allergies linked with covid is likely to demand anaphylaxis treatment.

Anaphylaxis Treatment Market Geographical Share

North America is the dominating region during the forecast period.

In terms of region, the global anaphylaxis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America accounted for the largest market share of the global anaphylaxis treatment Market in 2021, owing to the rise in the patient pool suffering from the condition. In addition, awareness of the allergic tests and fatalities due to various allergic conditions are projected to boost the growth of the regional anaphylaxis treatment market. Also, lifestyle changes, early diagnosis of specific allergies, and availability of anaphylaxis treatment are likely to boost the expansion of the anaphylaxis treatment market in North America. Some of the key players in the region are focusing on launching innovative products, including the generic version of epinephrine, for the anaphylaxis condition. This is projected to fuel market growth in the region.

Anaphylaxis Treatment Companies and Competitive Landscape

Some of the major players in the global anaphylaxis treatment market include ALK-Abelló A/S, Amneal Pharmaceuticals Inc, Adamis Pharmaceuticals Corporation, Kaleo Inc, Mylan N.V, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., among others. The market players develop cost-effective and robust solutions to gain market share. In November 2021, Supernus Pharmaceuticals Completed the Acquisition of Adamas Pharmaceuticals. This acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flow. This acquisition also released a new capsule named GOCOVRI, which is the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy and Osmolex ER (amantadine) extended-release tablets, approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. In January 2022, Amneal Pharmaceuticals, Inc. acquired Saol Therapeutics, a private specialty pharmaceutical company. Through this acquisition, the company develops Lioresal and LYVISPAHTM pipeline products under development. This acquisition expands Amneal’s commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market. Lioresal is an intrathecal baclofen product delivered through an implantable intrathecal pump for use in the management of severe spasticity of cerebral or spinal origin for the institutional market. This product has approximately $25 million in annual net revenue. And LYVISPAHTM is a baclofen oral granules specialty product available in 5, 10, and 20 mg.

The global anaphylaxis treatment market report would provide access to approximately 61 market data tables, 56 figures, and 170 pages.